A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children

Summary

VLA1553-322 is a multicenter, prospective, randomized, double-blind, phase 3 clinical trial evaluating VLA1553 in comparison to a comparator (Nimenrix®) for each stratum (age group). At least 3,000 male and female healthy children aged 1 to 11 years will be enrolled and randomized 3:1 to either VLA1553 (n=2,250) or comparator (Nimenrix®) (n=750).

Timeline

Start

2026-02-06

Primary completion

2026-12

Completion

2027-11

Drugs

Indications